Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: a randomized, open-label study.
CONCLUSION: In Asian patients with inadequately controlled T2DM while taking premixed insulin, the addition of empagliflozin for 24 weeks provided better glycaemic control and greater reductions in body weight and systolic blood pressure than the addition of linagliptin.
PMID: 32827752 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism - Category: Endocrinology Authors: Liu SC, Lee CC, Chuang SM, Sun FJ, Zeng YH Tags: Diabetes Metab Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Insulin | Jardiance | SGLT2 Inhibitors | Sodium | Study | Urinary Tract Infections